摘要
目的:研究瑞舒伐他汀对急性冠脉综合征患者择期经皮冠状动脉介入治疗(PCI)术后心功能、心肌损伤标志物的影响。方法:选择2018年5月~2019年5月本院收治的200例急性冠脉综合征择期实施PCI术患者作为研究对象,按照随机数字表法将其分为观察组和对照组,各100例。对照组在常规药物基础上予以辛伐他汀片治疗,观察组在常规药物基础上予以瑞舒伐他汀钙片治疗,两组均治疗6个月。比较两组治疗前和治疗后心功能[左室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]、心肌损伤标志物[肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白Ⅰ(cTnⅠ)、N末端B型钠尿肽前体(NT-pro BNP)]、血脂[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎症因子[高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)]以及治疗期间心血管不良事件发生情况。结果:治疗后,两组LVEF高于治疗前、LVESD和LVEDD低于治疗前,且观察组LVEF高于对照组、LVESD和LVEDD低于对照组(P<0.05)。治疗后,两组CK-MB、cTnⅠ、NT-pro BNP水平低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组TC、TG、LDL-C水平低于治疗前、HDL-C水平高于治疗前,且观察组TC、TG、LDL-C水平低于对照组、HDL-C水平高于对照组(P<0.05)。治疗后,两组hs-CRP、TNF-α、IL-6水平低于治疗前,且观察组低于对照组(P<0.05)。治疗期间,观察组心血管不良事件总发生率(10.00%)低于对照组(21.00%,P<0.05)。结论:瑞舒伐他汀能有效改善急性冠脉综合征患者PCI术后心功能,降低心肌损伤程度,改善机体血脂及炎症因子水平,减少术后心血管不良事件发生率。
Objective:To study the effects of rosuvastatin on cardiac function and myocardial injury markers in patients with acute coronary syndrome after elective percutaneous coronary intervention(PCI).Methods:200 patients with acute coronary syndrome who underwent PCI in our hospital from May 2018 to May 2019 were selected as research subjects.According to the random number table method,they were divided into observation group and control group,with 100 cases in each group.The control group was treated with simvastatin tablets on the basis of conventional drugs,and the observation group was treated with rosuvastatin calcium tablets on the basis of conventional drugs.Both groups were treated for 6 months.Cardiac function[left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD)],myocardial injury markers[creatine kinase isoenzyme(CK-MB),cardiac troponinⅠ(cTnⅠ),N-terminal pro-B-type natriuretic peptide(NT-pro BNP)],blood lipids[total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)],inflammatory factors[high sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]and incidence of cardiovascular adverse events were compared between two groups before and after treatment.Results:After treatment,LVEF in both groups was higher than that before treatment,LVESD and LVEDD were lower than those before treatment.LVEF in the observation group was higher than that in the control group,LVESD and LVEDD in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of CK-MB,cTnⅠand NT-pro BNP in both groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of TC,TG and LDL-C in both groups were lower than those before treatment,and the level of HDL-C was higher than that before treatment.The levels of TC,TG and L
作者
王同昂
华朋铎
符会妮
WANG Tong-ang;HUA Peng-duo;FU Hui-ni(Department of Cardiology,Nanyang Second People's Hospital,Nanyang 473000,China)
出处
《中国合理用药探索》
2021年第8期77-82,共6页
Chinese Journal of Rational Drug Use
